Propionyl-L-carnitine corrects metabolic and cardiovascular alterations in diet-induced obese mice and improves liver respiratory chain activity

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Mingorance, Carmen ^a   Duluc, Lucie ^b,c   Chalopin, Matthieu ^b,c   Simard, Gilles ^b,c,d   Ducluzeau, Pierre Henri ^b,c   Herrera, Maria Dolores ^a   Alvarez de Sotomayor, Maria ^a   Andriantsitohaina, Ramaroson ^b,c  

^a UNIVERSITY OF SEVILLE   (Spain)

^b LUNAM Universite   (France)

^c UNIVERSITÉ D'ANGERS   (France)

^d UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FATTY ACID; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PROPIONYLCARNITINE; TRIACYLGLYCEROL; CARNITINE; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FATTY ACID BLOOD LEVEL; FOOD INTAKE; HEART FUNCTION; HEART OUTPUT; INSULIN RESISTANCE; LIPID DIET; LIPOPROTEIN BLOOD LEVEL; LIVER MITOCHONDRION; METABOLIC DISORDER; MOUSE; MUSCLE MITOCHONDRION; NONHUMAN; OBESITY; RESPIRATORY CHAIN; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; WEIGHT GAIN; ANIMAL; C57BL MOUSE; DIET; ELECTRON TRANSPORT; FEEDING BEHAVIOR; LIVER; METABOLISM; ORGAN SIZE;

ANIMALIA; MUS;

ANIMALS; BODY WEIGHT; CARNITINE; DIET; ELECTRON TRANSPORT; FEEDING BEHAVIOR; LIVER; MICE; MICE, INBRED C57BL; ORGAN SIZE;

EID: 84858760357     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034268     Document Type: Article

References (43)

1. Kopelman PG, (2000) Obesity as a medical problem. Nature 404: 635-643.
2. Montague CT, O'Rahilly S, (2000) The perils of portliness: causes and consequences of visceral adiposity. Diabetes 49: 883-888.
3. Allende-Vigo MZ, (2010) Pathophysiologic mechanisms linking adipose tissue and cardiometabolic risk. Endocr Pract 16: 692-698.
4. Wiseman LR, Brogden RN, (1998) Propionyl-L-carnitine. Drugs Aging 12: 243-248.
5. Binienda Z, Virmani A, (2003) The mitochondriotropic effects of L-carnitine and its esters in the central nervous system. Curr Med Chem 3: 275-282.
6. Siliprandi N, Di Lisa F, Menabò R, (1991) Propionyl-L-carnitine: biochemical significance and possible role in cardiac metabolism. Cardiovasc Drugs Ther 5: 11-15.
7. Bueno R, Alvarez de Sotomayor M, Perez-Guerrero C, Gomez-Amores L, Vazquez CM, et al. (2005) L-Carnitine and propionyl-L-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: different participation of NO and COX-products. Life Sci 77: 2082-2097.
8. de Sotomayor MA, Mingorance C, Rodriguez-Rodriguez R, Marhuenda E, Herrera MD, (2007) l-carnitine and its propionate: improvement of endothelial function in SHR through superoxide dismutase-dependent mechanisms. Free Radic Res 4: 884-891.
9. Alvarez de Sotomayor M, Bueno R, Pérez-Guerrero C, Herrera MD, (2007) Effect of L-carnitine and propionyl-L-carnitine on endothelial function of small mesenteric arteries from SHR. J Vasc Res 44: 354-364.
10. Mynatt RL, (2009) Carnitine and type 2 diabetes. Diabetes Metab Res Rev 25 (Suppl 1): S45-S49.
11. Mingorance C, Gonzalez del Pozo M, Dolores Herrera M, Alvarez de Sotomayor M, (2009) Oral supplementation of propionyl-l-carnitine reduces body weight and hyperinsulinaemia in obese Zucker rats. Br J Nutr 102: 1145-1153.
12. Samuel VT, Petersen KF, Shulman GI, (2010) Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375: 2267-2277.
13. Gastaldelli A, Basta G, (2010) Ectopic fat and cardiovascular disease: what is the link? Nutr Metab Cardiovasc Dis 20: 481-490.
14. Micheletti R, Giacalone G, Bianchi G, (1996) Effect of propionyl-L-carnitine on the mechanics of right and left papillary muscles from volume-overloaded rat hearts. J Cardiovasc Pharmacol 27: 52-57.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
16. Agouni A, Mostefai HA, Porro C, Carusio N, Favre J, et al. (2007) Sonic hedgehog carried by microparticles corrects endothelial injury through nitric oxide release. Faseb J 21: 2735-2741.
17. Malgat MLT, Durrieu G, Mazat JP, (1999) Enzymatic and polarographic measurements of the respiratory chain complexes. Mitochondrial Diseases Patrick Lestiene (ed). Springer, Berlin.
18. Cha YS, Eun JS, Oh SH, (2003) Carnitine profiles during differentiation and effects of carnitine on differentiation of 3T3-L1 cells. J Med Food 6: 163-167.
19. Lee MS, Lee HJ, Lee HS, Kim Y, (2006) L-carnitine stimulates lipolysis via induction of the lipolytic gene expression and suppression of the adipogenic gene expression in 3T3-L1 adipocytes. J Med Food 9: 468-473.
20. Siegner R, Heuser S, Holtzmann U, Söhle J, Schepky A, et al. (2010) Lotus leaf extract and L-carnitine influence different processes during the adipocyte life cycle. Nutr Metab (Lond) 7: 66-76.
21. Després JP, Lemieux I, (2006) Abdominal obesity and metabolic syndrome. Nature 444: 881-887.
22. Amin KA, Nagy MA, (2009) Effect of Carnitine and herbal mixture extract on obesity induced by high fat diet in rats. Diabetol Metab Syndr 1: 17-31.
23. Power RA, Hulver MW, Zhang JY, Dubois J, Marchand RM, et al. (2007) Carnitine revisited: potential use as adjunctive treatment in diabetes. Diabetologia 50: 824-832.
24. Kleemann R, van Erk M, Verschuren L, van den Hoek AM, Koek M, et al. (2010) Time-resolved and tissue-specific systems analysis of the pathogenesis of insulin resistance. PLoS One 5: e8817.
25. Vial G, Dubouchaud H, Leverve XM, (2010) Liver mitochondria and insulin resistance. Acta Biochim Pol 57: 389-392.
26. Crescenzo R, Bianco F, Falcone I, Prisco M, Liverini G, et al. (2008) Alterations in hepatic mitochondrial compartment in a model of obesity and insulin resistance. Obesity (Silver Spring) 16: 958-64.
27. Vial G, Dubouchaud H, Couturier K, Cottet-Rousselle C, Taleux N, et al. (2010) Effects of a high-fat diet on energy metabolism and ROS production in rat liver. J Hepatol 54: 348-356.
28. Ortenblad N, Mogensen M, Petersen I, Højlund K, Levin K, et al. (2005) Reduced insulin-mediated citrate synthase activity in cultured skeletal muscle cells from patients with type 2 diabetes: evidence for an intrinsic oxidative enzyme defect. Biochim Biophys Acta 1741: 206-214.
29. Kashyap SR, Roman LJ, Lamont J, Masters BS, Bajaj M, et al. (2006) Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. J Clin Endocrinol Metab 90: 1100-5.
30. Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, et al. (2010) A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab 2: 483-495.
31. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, et al. (2008) Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 7: 45-56.
32. Noland RC, Koves TR, Seiler SE, Lum H, Lust RM, et al. (2009) Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. J Biol Chem 284: 22840-22852.
33. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, et al. (2009) Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr 139: 1073-1081.
34. Yu Q, Gao F, Ma XL, (2011) Insulin says NO to cardiovascular disease. Cardiovasc Res 89: 516-524.
35. Ketonen J, Shi J, Martonen E, Mervaala E, (2010) Periadventitial adipose tissue promotes endothelial dysfunction via oxidative stress in diet-induced obese C57Bl/6 mice. Circ J 74: 1479-1487.
36. Molnar J, Yu S, Mzhavia N, Pau C, Chereshnev I, et al. (2005) Diabetes induces endothelial dysfunction but does not increase neointimal formation in high-fat diet fed C57BL/6J mice. Circ Res 96: 1178-1184.
37. Galinier M, Pathak A, Roncalli J, Massabuau P, (2005) Obesity and cardiac failure. Arch Mal Coeur Vaiss 98: 39-45.
38. Fang CX, Dong F, Thomas DP, Ma H, He L, et al. (2008) Hypertrophic cardiomyopathy in high-fat diet-induced obesity: role of suppression of forkhead transcription factor and atrophy gene transcription. Am J Physiol Heart Circ Physiol 295: H1206-H1215.
39. Rodriguez WE, Joshua IJ, Falcone JC, Tyagi SC, (2006) Pioglitazone prevents cardiac remodeling in high-fat, high-calorie-induced Type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol 291: H81-H87.
40. Ussher JR, Koves TR, Jaswal JS, Zhang L, Ilkayeva O, et al. (2009) Insulin-stimulated cardiac glucose oxidation is increased in high-fat diet-induced obese mice lacking malonyl CoA decarboxylase. Diabetes 58: 1766-1775.
41. Coffey JP, Hill JC, (2005) Cardiac output and index in obese and non-obese patients using gated single photon emission computed tomography sestamibi perfusion imaging. J HK Coll Radiol 8: 226-232.
42. Mingorance C, Rodriguez-Rodriguez R, Justo ML, Herrera MD, Alvarez de Sotomayor M, (2011) Propionyl-L-carnitine: an overview of its pharmacological effects and clinical applications. Nutr Rev 69: 279-290.
43. Calvani M, Reda E, Arrigoni-Martelli E, (2000) Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol 95: 75-83.